Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)R&D In ProcessReceivables - NetShares OutstandingShares Outstanding
Ratios

Tandem Diabetes Care (TNDM) EBIAT (2016 - 2026)

Tandem Diabetes Care filings provide 13 years of EBIAT readings, the most recent being -$589000.0 for Q4 2025.

  • On a quarterly basis, EBIAT fell 178.01% to -$589000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was -$204.7 million, a 113.18% decrease, with the full-year FY2025 number at -$204.7 million, down 113.18% from a year prior.
  • EBIAT hit -$589000.0 in Q4 2025 for Tandem Diabetes Care, up from -$21.2 million in the prior quarter.
  • In the past five years, EBIAT ranged from a high of $10.8 million in Q4 2021 to a low of -$130.6 million in Q1 2025.
  • Median EBIAT over the past 5 years was -$22.2 million (2024), compared with a mean of -$30.1 million.
  • Biggest five-year swings in EBIAT: surged 161.59% in 2021 and later crashed 945.18% in 2022.
  • Tandem Diabetes Care's EBIAT stood at $10.8 million in 2021, then plummeted by 246.67% to -$15.9 million in 2022, then plummeted by 89.26% to -$30.0 million in 2023, then surged by 102.52% to $755000.0 in 2024, then tumbled by 178.01% to -$589000.0 in 2025.
  • The last three reported values for EBIAT were -$589000.0 (Q4 2025), -$21.2 million (Q3 2025), and -$52.4 million (Q2 2025) per Business Quant data.